Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV
Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV
Staten Island, New York--(Newsfile Corp. - March 21, 2024) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024. The event is expected to feature 80 companies presenting in half-hour increments, as well as private 1:1 meetings.
紐約史泰登島--（Newsfile Corp.-2024 年 3 月 21 日）- Acurx 製藥公司 納斯達克股票代碼：ACXP）今天宣佈，它將於2024年4月8日至9日在紐約索菲特酒店舉行的第14屆年度LD Micro邀請賽上亮相。該活動預計將有80家公司以半小時爲單位參加，並舉行私人1：1會議。
Acurx Pharmaceuticals, Inc. is scheduled to present on April 8th at 2:30 pm ET. David P. Luci will be leading the presentation.
Acurx Pharmicals, Inc.定於美國東部時間4月8日下午 2:30 上市。大衛·P·盧奇將主持演講。
We invite interested parties to register to watch the presentation virtually here.
我們邀請感興趣的人士註冊在此處虛擬觀看演講。
About Acurx Pharmaceuticals, Inc.
關於 Acurx Pharmicals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company is preparing to advance its lead antibiotic candidate to international Phase 3 clinical trials forC. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic and the first of a new class of DNA pol IIIC inhibitors under development by Acurx. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including C. difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).To learn more about Acurx Pharmaceuticals and its product pipeline, please visit .
Acurx Pharmaceuticals是一家處於後期階段的生物製藥公司，專注於開發一類針對難以治療的細菌感染的新型小分子抗生素。該公司正準備將其主要候選抗生素推進艱難梭菌感染（CDI）的3期國際臨床試驗。Ibezapolstat是一種新型的口服抗生素，也是Acurx正在開發的新一類DNA pol IIIC抑制劑中的第一種。該公司的方法是開發具有革蘭氏陽性選擇譜（GPSS）的候選抗生素，該光譜可阻斷革蘭氏特異性細菌酶DNA聚合酶IIIC（pol IIIC）的活性位點，抑制DNA複製並導致革蘭氏陽性細菌細胞死亡。其研發管道包括針對革蘭氏陽性細菌的候選抗生素產品，包括艱難梭菌、耐甲氧西林金黃色葡萄球菌（MRSA）、耐萬古黴素腸球菌（VRE）和耐藥肺炎鏈球菌（DRSP）。要了解有關Acurx Pharmicals及其產品管線的更多信息，請訪問。
About LD Micro
關於 LD Micro
LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Whether it is the Index, comprehensive data, or hosting the most significant events annually, LD's sole mission is to serve as an invaluable asset for all those interested in finding the next generation of great companies. For more information on LD Micro, visit .
LD Micro是美國自由市場的全資子公司，成立於2006年，其唯一目的是成爲微型股領域的獨立資源。無論是指數、綜合數據，還是每年舉辦最重要的活動，LD的唯一使命是爲所有有興趣尋找下一代優秀公司的人提供寶貴的資產。有關 LD Micro 的更多信息，請訪問。
Please reach out to the company representative below or Dean Summers (dean@ldmicro.com) to register for the event and schedule a meeting with the company.
請聯繫下面的公司代表或迪恩·薩默斯（dean@ldmicro.com）註冊活動並安排與公司的會面。
To learn more about Freedom US Markets, visit
要了解有關 Freedom US Markets 的更多信息，請訪問
For further information on Acurx Pharmaceuticals, Inc.:
有關 Acurx Pharmicals, Inc. 的更多信息：
David P. Luci
President & CEO
9175331469
davidluci@acurxpharma.com
大衛 P. Luci
總裁兼首席執行官
9175331469
davidluci@acurxpharma.com
譯文內容由第三人軟體翻譯。